Davide Melisi
University of Verona
CancerInternal medicineOncologyImmunologyChemotherapyFOLFIRINOXPancreatic cancerGemcitabineIrinotecanAngiogenesisPopulationMetastatic Pancreatic AdenocarcinomaIn patientCancer researchColorectal cancerSignal transductionMedicineBiologyGastroenterologyCancer cellPharmacology
Publications 205
#1Timothy A. Yap (University of Texas MD Anderson Cancer Center)H-Index: 24
#2Maria Vieito (Hebron University)H-Index: 11
Last. Antoine F. Carpentier (University of Paris)H-Index: 47
view all 24 authors...
Purpose: null A novel, selective, next-generation transforming growth factor beta (TGFβ) receptor type-1 small molecule inhibitor, LY3200882, demonstrated promising preclinical data. This first-in-human trial evaluated safety, tolerability, recommended phase II dose (RP2D), pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of LY3200882 as monotherapy or with other anticancer agents in patients with advanced cancer. null Patients and Methods: null This phase I multicenter stu...
#1Fabio Sabbadini (University of Verona)H-Index: 2
#2Monica Bertolini (University of Verona)
Last. Davide Melisi (University of Verona)H-Index: 31
view all 7 authors...
Transforming growth factor-beta (TGF-β) is a secreted cytokine that signals via serine/threonine kinase receptors and SMAD effectors. Although TGF-β acts as a tumor suppressor during the early stages of tumorigenesis, it supports tumor progression in advanced stages. Indeed, TGF-β can modulate the tumor microenvironment by modifying the extracellular matrix and by sustaining a paracrine interaction between neighboring cells. Due to its critical role in cancer development and progression, a wide ...
#1Nikunj Patel (AstraZeneca)H-Index: 3
Last. O. Meyers
view all 13 authors...
INTRODUCTION Patients living with biliary tract cancer (BTC) experience a decline in health-related quality of life (HRQoL). This study aimed to obtain a comprehensive understanding of the patient experience of BTC-related signs/symptoms and the impacts of these on daily functioning and HRQoL. METHODS Patients with BTC participated in qualitative semi-structured concept elicitation interviews. Signs/symptoms and impacts of BTC were initially explored by targeted literature searches and interview...
#1Ghassan K. Abou-Alfa (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 52
#2Vaibhav Sahai (UM: University of Michigan)H-Index: 24
Last. Adrian Murphy (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 14
view all 19 authors...
#1T. Bekaii-Saab (Mayo Clinic)H-Index: 9
#2Juan W Valle (University of Manchester)H-Index: 61
Last. Mitesh J. Borad (Mayo Clinic)H-Index: 43
view all 0 authors...
#1Davide MelisiH-Index: 31
Last. Giovanni ButturiniH-Index: 51
view all 21 authors...
Abstract Background Pancreaticoduodenal cancer (PDC) is a group of malignant tumors arising in the ampullary region, which lack approved targeted therapies for their treatment. Methods This retrospective, observational study is based on Secondary Data Use (SDU) previously collected during a multicenter collaboration, which were subsequently entered into a predefined database and analyzed. FoundationOne CDx or Liquid, a next-generation DNA sequencing (NGS) service, was used to identify genomic al...
#1Valeria Merz (University of Verona)H-Index: 9
#2Marina Gaule (University of Verona)H-Index: 3
Last. Davide Melisi (University of Verona)H-Index: 31
view all 13 authors...
Mutations of the proto-oncogene KRAS are the most frequent gain-of-function alterations found in cancer. KRAS is mutated in about 30% of all human tumors, but it could reach more than 90% in certain cancer types such as pancreatic adenocarcinoma. Although historically considered to be undruggable, a particular KRAS mutation, the G12C variant, has recently emerged as an actionable alteration especially in non-small cell lung cancer (NSCLC). KRASG12C and pan-KRAS inhibitors are being tested in cli...
3 CitationsSource
#1Alfredo CarratoH-Index: 67
#2Davide Melisi (University of Verona)H-Index: 31
Last. Teresa Macarulla Mercade (Hebron University)H-Index: 5
view all 8 authors...
Aim: To survey European physicians managing patients with metastatic pancreatic ductal adenocarcinoma (PDAC) and understand differences in baseline characteristics, diagnostic methods, symptoms and co-morbidities. Materials & methods: Patient record inclusion criteria were: ≥18 years old, metastatic PDAC diagnosis and completion of first-line treatment between July 2014 and January 2016. Records were grouped by patient age, gender and primary tumor location. Results: Records (n = 2565) were coll...